Search

Search Constraints

You searched for: Author/Creator Levy, Howard

Search Results

1. A framework for the classification of joint hypermobility and related conditions. Issue 1 (1st February 2017)

4. Final Results of the RHAPSODY Trial: A Multi‐Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A‐APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Issue 1 (7th January 2019)

5. Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): Clinical description and natural history. Issue 1 (1st February 2017)

6. Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. (24th March 2021)

7. Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Issue 12 (December 2016)

8. Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. Issue 6 (17th August 2021)

9. The 2017 international classification of the Ehlers–Danlos syndromes. Issue 1 (March 2017)

10. The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso‐occlusive crises. Issue 6 (29th April 2017)